



**CSE: IN**  
**OTCQB: IMLFF**

Suite 340-200 Granville St.  
Vancouver, BC, Canada V6C-1S4  
Tel: 604.669.7207  
Email: [info@inmedpharma.com](mailto:info@inmedpharma.com)  
[www.inmedpharma.com](http://www.inmedpharma.com)

## **InMed Clarifies 3<sup>rd</sup> Party News Coverage**

Vancouver, BC – December 20, 2017 - **InMed Pharmaceuticals, Inc.** ("InMed" or the "Company") (CSE:IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, wishes to clarify a 3<sup>rd</sup> party publication released today by Cannabis News Wire.

The article comments on InMed's drug pipeline, INM-750, for the treatment of Epidermolysis Bullosa, a INM-085, for the treatment of Glaucoma and INM-405 for the pain market. InMed's clarifies that the revenue numbers quoted were directed at the revenue potential for the disease category and not the revenue potential for InMed's therapeutic products. The article was not paid for by InMed nor was any compensation provided.

### **About InMed**

InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's bioinformatics platform, its biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit [www.inmedpharma.com](http://www.inmedpharma.com).

### **Contact: InMed Pharmaceuticals Inc.**

Chris Bogart  
Investor Relations  
T: 604.669.7207  
E: [chris@inmedpharma.com](mailto:chris@inmedpharma.com)

### **Cautionary Note Regarding Forward-Looking Information**

*This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: the use of net proceeds from the proposed private placement; receiving all necessary regulatory approvals for the proposed private placement; and the expected fundamental value drivers of the Company.*

*With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: receipt of all necessary regulatory approvals for the proposed private placement; successful completion of the proposed private placement; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.*

*Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: InMed may not complete the proposed private placement; InMed may not receive all necessary regulatory approvals for the proposed private placement; InMed may not use net proceeds received from the proposed private placement as currently contemplated and InMed's bioinformatics platform, biosynthesis manufacturing process and drug development programs may not return their expected level of value.*

*A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed's Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at [www.sedar.com](http://www.sedar.com). All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.*

*This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.*

*NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.*